Skip to main content
. 2023 Apr 19;115(7):831–837. doi: 10.1093/jnci/djad070

Figure 4.

Figure 4.

A) Incidence of acute kidney injury (AKI) by stage among patients with sustained and transient AKI. B) Etiology of sustained AKI among olaparib-treated and niraparib-treated patients. Sustained AKI was defined as a persistent elevation of serum creatinine of at least 1.5-fold from baseline for 2 or more consecutive days within the first year after therapy initiation. PARPi = poly (ADP-ribose) polymerase inhibitor.